Open Innovation in the Pharmaceutical Industry: An Empirical Analysis on Context Features, Internal R&D, and Financial Performances

2015 ◽  
Vol 62 (3) ◽  
pp. 421-435 ◽  
Author(s):  
Francesca Michelino ◽  
Emilia Lamberti ◽  
Antonello Cammarano ◽  
Mauro Caputo
Keyword(s):  
Pharmaceutical Industry ◽  
Empirical Analysis ◽  
Open Innovation ◽  
Context Features

scholarly journals Open innovation: An opportunity for Pharmerging countries to close the technology gap?

2014 ◽  
Vol 5 (1) ◽  
pp. 19
Author(s):  
Hind Louiza Chitour
Keyword(s):  
Pharmaceutical Industry ◽  
Open Innovation ◽  
Health Expenditures ◽  
Pharmaceutical Companies ◽  
Closed Model ◽  
Health Market ◽  
Intangible Benefits ◽  
Critical Phase ◽  
Innovation Model ◽  
The Impact

The pharmaceutical industry is entering a critical phase in its history, with decliningprofits and patent cliffs fallouts awaiting their former blockbuster drugs. Several hypotheseshave been formulated to explain the causes of this downfall whether it is the drought in theirR&D pipelines, the rising competition of generics or the ever-increasingpressure from healthcareproviders such as governments seeking to curb their health expenditures thus causing priceerosion. However, rather than striving to find the root causes of the issues the industry isfacing, the major players in the Pharma field should focus on implementing measures totransform the very structure of the pharmaceutical companies and change the drug discoveryand commercialization processes. These core changes that the pharmaceutical sector has toundergo could be achieved through several methods. One of the most suggested solutions tothis R&D bottleneck could be shifting from the traditional “closed model” towards a new “openinnovation” model based on collaboration of Pharma companies whether it includes workingtogether with a biotech company, CROs, Academia or local Pharma manufacturer. This openinnovation model is believed to foster innovation and invigorate the agonizing R&D Pharmasector as it proved itself to be effective resulting in innovative projects and ideas in the ITsector. It is in this context that this paper will address the opportunity emerging pharmaceuticalmarkets could benefit from when this open innovation model is applied to the pharmaceuticalindustry. Mainly, we will discuss the integration of this strategy within big Pharma companiesin their efforts to enter what is designated as “Pharmerging countries” in general with a specialfocus on one key global health market: China. We will discuss the impact of this innovationstrategy could bring in terms of both tangible and intangible benefits and potential drawbacks.

scholarly journals KNOWLEDGE IN OPEN INNOVATION PROCESS ON AN EXAMPLE OF PHARMACEUTICAL INDUSTRY

2017 ◽  
pp. 274-289
Author(s):  
Elżbieta Pohulak-Żołędowska ◽  
Arkadiusz Żabiński ◽  
Michał Sosnowski
Keyword(s):  
Pharmaceutical Industry ◽  
Open Innovation ◽  
Innovation Process

Crowdsourcing in Innovation Activity of Enterprises on an Example of Pharmaceutical Industry

2019 ◽  
pp. 58-70
Author(s):  
Elżbieta Pohulak-Żołędowska
Keyword(s):  
Pharmaceutical Industry ◽  
Knowledge Economy ◽  
Open Innovation ◽  
Production Costs ◽  
The Other ◽  
New Drugs ◽  
Knowledge Flow ◽  
Innovation Activity ◽  
Information Goods ◽  
Innovation Model

The chapter considers issues connected with innovation creation in open innovation model. The knowledge flow in open innovation has been presented. The main “product” of knowledge economy—innovations (as a concept)—are symbolic goods, founded in symbols – not in atoms. This notion causes some consequences typical for information goods, like ease of replication or exchange, zero-marginal replication costs, and cheap storage. On the other hand, there are growing innovation production costs, and uncertainty and risk of innovation activity that discourage companies from being innovative. The idea of open innovation is being used in pharmaceutical industry more and more often in order to cut innovation costs and shorten the new drugs pipelines. One of the most “open” dimensions of innovation activity in pharmaceutical industry is crowdsourcing: a specific sourcing model, an internet-enabled business model that harnesses the creative ability of agents external to organization.

Sign in / Sign up

Export Citation Format

Share Document